IMPORTANCE Studies of mechanically ventilated critically ill patients that combine populations that are at high and low risk for reintubation suggest that conditioned high-flow nasal cannula oxygen therapy after extubation improves oxygenation compared with conventional oxygen therapy. However, conclusive data about reintubation are lacking.
percapnic respiratory failure in patients with chronic obstructive pulmonary disease 2 ). Preventive noninvasive positivepressure ventilation has failed to mitigate postextubation respiratory failure in the general population of critically ill patients, 3 although 2 randomized trials found evidence for its effectiveness in specific subgroups of patients with high-risk factors for reintubation. 4, 5 Technological improvements have enabled high-flow oxygen therapy to be delivered through nasal cannula. This mode now not only allows constant FIO 2 during peak inspiratory flow but also confers benefits such as a low level of continuous positive airway pressure 6 with increased end-expiratory lung volume 7 and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. 8 The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, 9 leading to improved drainage of respiratory secretions. 10 Clinical studies in general populations of critically ill patients have found that high-flow therapy during the acute phase of respiratory failure improves oxygenation, survival, 11 tolerance and comfort, 9, 10 and ease of respiratory secretions drainage. 12 High-flow therapy after extubation has demonstrated clinical benefits in specific populations such as preterm infants 13 and patients undergoing cardiac surgery. 14 Recently, Maggiore et al 10 suggested that high-flow therapy after planned extubation decreased the reintubation rate in a general population of critical patients, but the benefits observed in the general population might be mainly attributable to improvements in high-risk patients. This study aimed to determine whether high-flow oxygen therapy immediately after planned extubation would reduce the need for reintubation compared with standard oxygen therapy in patients at low risk for reintubation.
Methods
From September 2012 to October 2014, the randomized clinical trial was carried out in 7 intensive care units (ICUs) in Spain. The ethics committee at each hospital and the departments of health of the regional governments with which these hospitals are affiliated (Madrid, Castilla-la Mancha, Catalonia, and Balearic Islands) approved the study protocol (protocol available in Supplement 1). All patients or their relatives provided written informed consent, and none received a stipend.
Patients
All adult patients receiving mechanical ventilation longer than 12 hours were eligible. Patients were recruited when ready for scheduled extubation after tolerating a spontaneous breathing trial (eAppendix 1 in Supplement 2), provided they met the criteria for low risk of reintubation: younger than 65 years 4, 5 ; absence of heart failure as the primary indication for mechanical ventilation 4, 5 ; absence of moderate-to-severe chronic obstructive pulmonary disease 15 ; Acute Physiology and Chronic Health Evaluation (APACHE) II score less than 12 points on day of extubation 4, 5 ; body mass index less than 30 (calculated as weight in kilograms divided by height in meters squared) 2, 16 ;
absence of airway patency problems, including high risk of developing laryngeal edema (eAppendix 2 in Supplement 2)
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; ability to manage respiratory secretions (adequate cough reflex or suctioning <2 times within 8 hours before extubation) 5, 17 ;
simple weaning (eAppendix 3 in Supplement 2) 5 ; fewer than 2 comorbidities (eAppendix 4 in Supplement 2) 5 ; and no prolonged mechanical ventilation, defined as longer than 7 days. 18 Patients who had do-not-resuscitate orders, had tracheostomies, or were accidentally extubated or self-extubated were excluded. Patients who were hypercapnic during the spontaneous breathing trial were also excluded, because most physicians preferred to use preventive noninvasive ventilation instead of ordinary oxygen or high-flow therapy.
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At inclusion, demographic variables (age, sex, APACHE II score within first 24 hours after admission) and primary diagnosis were recorded. At extubation, the following variables were recorded: arterial blood gas levels, APACHE II score, and administration of steroids. In the 72 hours after extubation, the following variables were recorded: extubation-related complications, nasal septum and skin trauma as surrogates for adverse events, reasons for reintubation, and time to reintubation in hours. Patients were followed up until discharge from the hospital. Length of stay in the ICU and in the hospital and status at discharge from the hospital were recorded.
Weaning Protocol
The clinical weaning protocol included daily screening for weaning readiness according to the following criteria 19 : recovery from the precipitating illness; respiratory criteria (PaO 2 :FIO 2 ratio >150 mm Hg with FIO 2 ≤0.4, positive end-expiratory pressure <8 cm H 2 O, and arterial pH >7.35); and clinical criteria (absence of electrocardiographic signs of myocardial ischemia, no vasoactive drugs or only low doses of dopamine [<5 μg/kg/min], heart rate <140/min, hemoglobin >8 g/dL, temperature <38°C, no need for sedatives, presence of respiratory stimulus, and appropriate spontaneous cough). Patients fulfilling these criteria underwent a spontaneous breathing trial with either T-tube or 7 cm H 2 O of pressure support for 30 to 120 minutes. Standard criteria for failure of the spontaneous breathing trial were used (eAppendix 1 in Supplement 2). Patients who tolerated the spontaneous breathing trial were reconnected with the previous ventilator settings for rest and clinical evaluation of airway patency, respiratory secretions, and upper airway obstruction (eAppendix 2 in Supplement 2).
Randomization
Before scheduled extubation, patients who passed the spontaneous breathing trial were randomized to receive conventional oxygen therapy or high-flow therapy by concealed allocation with a random-number generator (constant permuted
Interventions
High-flow oxygen therapy (Optiflow; Fisher & Paykel Healthcare) was applied immediately after extubation through nasal cannula. Flow was initially set at 10 L/min and titrated upward in 5-L/min steps until patients experienced discomfort. Temperature was initially set to 37°C, unless reported too hot by patients, and FIO 2 was regularly adjusted to target peripheral capillary oxygen saturation (SpO 2 ) greater than 92%. After 24 hours, high-flow therapy was stopped and, if necessary, patients received conventional oxygen therapy.
Conventional oxygen therapy was applied continuously through nasal cannula or nonrebreather facemask, and oxygen flow was adjusted to maintain SpO 2 greater than 92%.
Both groups were treated by the same medical, nursing, and respiratory therapy staff (excluding the investigators) and received similar medical management. Assisting physicians could not be blinded to the study group. To reduce this unavoidable bias, investigators did not participate in clinical decisions, and statistical analyses were performed in a blinded fashion.
Outcomes
The primary outcome was reintubation within 72 hours after extubation. Predefined criteria for immediate respiratoryrelated reintubation included any of the following major clinical events: respiratory or cardiac arrest, respiratory pauses with loss of consciousness or gasping for air, psychomotor agitation inadequately controlled by sedation, massive aspiration, persistent inability to remove respiratory secretions, heart rate less than 50/min with loss of alertness, or severe hemodynamic instability unresponsive to fluids and vasoactive drugs. Patients also were reintubated for persistent postextubation respiratory failure (defined in the next paragraph; see also eAppendix 5 in Supplement 2) or for nonrespiratory reasons (ie, without fulfilling postextubation respiratory failure criteria), such as urgent surgery or a low level of consciousness (decrease in Glasgow Coma Scale [GCS] score >2 points or GCS score <9 points) with PaCO 2 less than 45 mm Hg.
Secondary outcomes were postextubation respiratory failure and respiratory infection (ventilator-associated pneumonia or ventilator-associated tracheobronchitis; see eAppendix 6 in Supplement 2). Postextubation respiratory failure was defined as the presence of any of the following criteria within 72 hours of extubation: respiratory acidosis (pH <7.35 with PaCO 2 >45 mm Hg), SpO 2 less than 90% or PaO 2 less than 60 mm Hg at FIO 2 greater than 0.4, respiratory rate greater than 35/min, decreased level of consciousness (defined as a decrease in GCS score >1 point), agitation, or clinical signs suggestive of respiratory muscle fatigue, increased work of breathing (eg, the use of respiratory accessory muscles, paradoxical abdominal motion, or retraction of the intercostal spaces), or both. 20 Delayed reintubation was considered the main safety concern, and time to reintubation was measured as a safety surrogate. Rescue therapy with noninvasive mechanical ventilation for postextubation respiratory failure was strongly discouraged.
Additional secondary outcomes included sepsis, multiorgan failure, ICU and hospital length of stay and mortality, time to reintubation, and adverse effects (study protocol, Supplement 1).
Statistical Analysis
Based on a previous study, the absolute reduction in reintubation rate was estimated at 8%, from a basal rate of 13%. 21 In an effort to achieve 80% power to detect that difference, a sample size of 260 patients in each group of the study was considered adequate for a 2-sided test, an α level of 5%, and a maximum tolerated patient loss rate of 15%. All analyses were performed on an intention-to-treat basis. Kaplan-Meier curves were plotted to assess the time from extubation to reintubation and compared by means of the log-rank test.
To assess the probability of reintubation, the CochranMantel-Haenszel χ 2 test stratified according to recruiting hospital was used. To test whether the marginal odds ratio (OR) of high-flow therapy was similar to the OR conditioned to covariables, a multivariable logistic regression was used. The independent variables tested in the model were high-flow oxygen therapy, length of mechanical ventilation, hospital, and all the variables associated with reintubation that had P values less than .10 (eAppendix 7 in Supplement 2, bottom 
Results
During the study period, 1739 weanable patients receiving mechanical ventilation for longer than 12 hours were identified; of these, 527 (30%) were randomized: 264 to the high-flow group and 263 to the conventional group ( Figure 1 ). There were no dropouts from the study. Demographic and clinical characteristics of patients in the 2 groups were similar ( 2.5% to 12.2%]; P = .004). This difference was mainly attributable to a lower incidence of respiratory-related reintubation in the high-flow group: 1.5% vs 8.7% in the conventional group (absolute difference, 7.2% [95% CI, 3.6% to 11.4%]; P = .001) ( Table 2 and Figure 2 ). In the multivariable analysis, high-flow therapy was independently and inversely associated with all-cause reintubation (OR, 0.32 [95% CI, 0.16 to 0.66]) (eAppendix 7 in Supplement 2, top table) and respiratory-related reintubation (OR, 0.17 [95% CI, 0.06 to 0.51]). The number of patients needed to treat to prevent 1 reintubation with high-flow therapy was 14 (95% CI, 8 to 40). The statistical analysis was repeated after excluding the 7 reintubations secondary to laryngeal edema (4.9% vs 9.8%, P = .04).
Secondary Outcomes
Postextubation respiratory failure was less common in the highflow group: 22 patients (8.3%) vs 38 patients (14.4%) in the conventional group (absolute difference, 6.1% [95% CI, 0.7% to 11.6%]; P = .03). Differences in other secondary outcomes were not statistically significant between the 2 groups ( Table 2 and  Table 3 ).
After adjusting all secondary outcomes for multiple comparisons, only FIO 2 12 hours after extubation (P < .001), laryngeal edema requiring reintubation (P = .02), and respiratorycauses reintubation (P = .02) remained statistically significant.
Differences in the median time to reintubation were not statistically significant between the 2 groups, for either all reintubations (19 in the conventional group; absolute difference, 7.2% [95% CI, 3.6% to 11.4%]; P = .10). Figure 2 shows the Kaplan-Meier curves for all-causesrelated reintubations. After the 72-hour follow-up period, patients were reintubated only for surgical procedures; none of these patients had respiratory failure or extubation failure.
The difference in the median ICU length of stay was not statistically significant (6 days [IQR, [2] [3] [4] [5] [6] [7] [8] No adverse effects were detected: all patients tolerated the high-flow nasal cannulae, and no nasal mucosa or skin traumas were reported.
Discussion
The main finding of this study was that high-flow oxygen significantly reduced the reintubation rate in critically ill patients at low risk for extubation failure. The reintubation rate in the control group receiving conventional oxygen therapy The proportion of patients reintubated for nonrespiratoryrelated causes depends mainly on the case mix, which varies widely among ICUs, and has not usually been reported in clinical studies. In the present study, up to 30% of reintubations were related to nonrespiratory causes, because the case mix included high proportions of postsurgical and neurocritical patients. After excluding these causes, the reintubation rate in the present study was low enough to be comparable to what is expected in a low-risk population (1.5% vs 8.7%).
Delaying intubation or reintubation can be deleterious. This lack of delay is probably attributable to the low-risk population and the protocol, which limited high-flow therapy to 24 hours after extubation. High-flow therapy increases comfort and oxygenation 10 and may disguise respiratory distress for an extended period, so the 24-hour limit probably helped physicians appreciate undertreated respiratory distress at an early stage. The downside of the 24-hour time limit is that improvements in secretions management favored by gas conditioning in high-flow therapy may be time-dependent 10 (the longer the time under high flow, the greater the expected improvement). However, the results confirmed that 24-hour high-flow therapy was enough to reduce the rate of reintubation for the inability to clear secretions in low-risk patients. The use of high-flow therapy was restricted to 24 hours after extubation because 24 hours is the standard monitoring time before ICU discharge in the study environment, and at the time patients were recruited, there were no devices able to apply high-flow therapy without a source of medical air, which is not always available in the ward. However, the optimal length of high-flow therapy is unknown. Maggiore et al 10 randomized a general population of critically ill patients to receive either high-flow therapy or conventional therapy for 48 hours. They found better oxygenation in the high-flow group starting from 24 hours after initiating treatment and achieved a low reintubation rate (3.8%) in the high-flow group. On the other hand, as suggested by Kang et al, 27 applying high-flow therapy up to 7 days according to clinical response could lead to delayed intubation associated with worse outcome. Until addi- lower rate of reintubation secondary to hypoxia in the highflow group corroborates this finding. High-flow oxygen also seems to reduce other causes of respiratory failure such as increased work of breathing and respiratory muscle fatigue, [6] [7] [8] which are frequently associated with reintubation secondary to hypoxia. Another way in which high-flow therapy improves extubation outcome is by conditioning the inspired gas. 9 Maggiore et al 10 demonstrated that high-flow oxygen improves the management of respiratory secretions, and the lower rate of reintubations secondary to upper airway obstruction ditioning probably alleviates inflammation of the tracheal mucosa after transglottic intubation; in the present study, the application of totally conditioned high-flow oxygen through a nasal cannula at extubation (aimed to block the entrance of dry and cold air in the patients' native airway), and the lower rate of upper airway obstruction, suggests this strategy was effective, lending weight to this idea. However, given the short use of high-flow oxygen after extubation in this study, other possible mechanisms that are not time dependent cannot be ruled out. To exclude a bias in these results secondary to a difference in the number of patients with stridor, the statistical analysis was repeated after excluding these patients, confirming that there is no heterogeneity in the odds ratio.
Although lower reintubation rates would be expected to shorten ICU and hospital stays, 4, 19 no differences in these secondary outcomes were found, probably because the percentage of reintubated patients was too low to affect outcome variables in the entire group. The high rate of nonrespiratory-related reintubation and the high proportion of neurocritical patients also might account for this lack of difference in these outcomes. Differences in mortality were not expected, owing to the low mortality rate in this low-risk population. However, the wide confidence intervals observed in the analysis of secondary and exploratory outcomes-probably related to an inadequate sample size, not calculated for these outcomes-limits definite conclusions about these results.
Study Limitations
To select patients at low risk for reintubation, high-risk factors were selected mainly based on those reported in studies by Nava et al 5 The greater proportion of patients with medical diagnoses at admission in the control group could have some effect on the results; however, a sensitivity analysis showed no difference (eAppendix 8 in Supplement 2). The case mix in the present study included a high percentage of surgical and neurocritical patients, and this could account for the high proportion of non-respiratory-related reintubations and the great improvement in reintubation secondary to inability to clear respiratory secretions. However, another sensitivity analysis rejected any significant impact of neurologic diseases in the results (see eAppendix 8 in Supplement 2). In addition, these post hoc analyses suggest that the benefit could vary with the patient's diagnosis at admission.
The final decision to reintubate was determined by clinical criteria, and the single most relevant reason for reintubation was recorded. However, reintubation can sometimes be attributed to simultaneous causes, making it difficult to interpret these results.
Attending physicians could not be blinded to the study group. To reduce this unavoidable bias, investigators were excluded from clinical decisions. Another limitation is that FIO 2 was not truly reliable in the control group. Most patients were receiving oxygen via face mask immediately after extubation, and many of them were switched to nasal cannula in the 24 hours after extubation; however, the type of oxygen delivery device was not recorded after 24 hours.
Conclusions
Among extubated patients at low risk for reintubation, the use of high-flow nasal cannula oxygen compared with conventional oxygen therapy reduced the risk of reintubation within 72 hours. 
